Skip to content

Skin Toxicity by Oncological Therapies

Observational Study on Skin Toxicity by Oncological Therapies

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05109858
Acronym
SKINTOX
Enrollment
334
Registered
2021-11-05
Start date
2019-03-21
Completion date
2025-02-28
Last updated
2025-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Toxicity

Keywords

skin toxicities, oncological therapies

Brief summary

This is a multicenter, retrospective and prospective observational study. The project involves the collection of clinical data of patients treated with oncological therapies, to evaluate skin toxicities related to oncological treatment.

Detailed description

This is a multicenter, retrospective and prospective observational study. The research will include 300 patients treated with clinical practice oncological treatments (approved by Italian Competent Authority, AIFA) from January 2012 to February 2024. Patients will follow the prescribed therapeutic indications according to regular clinical practice and data from their medical records will be collected in a study database. Primary objective of the study is the evaluation of the type, frequency and severity of skin toxicities related to oncological treatment. Secondary objectives are: * Evaluation of the association between skin toxicities due to oncological treatment and drug activity and effectiveness parameters(ORR, PFS, OS); * Evaluation of the association between clinical-pathological features of primary cancer and skin toxicities of oncological treatment; * Evaluation of the optimal management of skin toxicities related to cancer treatment.

Interventions

None listed

Sponsors

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Patient who have signed informed consent. 2. Consecutive retrospective patients and prospective patients treated with new clinical practice oncological treatments (approved by AIFA) from January 2012 to February 2024 3. Male or female, age ≥18 years.

Exclusion criteria

Participation in another clinical trial with any investigational drug.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of the frequency of skin toxicities related to oncological treatment5 yearsAbsolute and (percentage) relative frequencies will be calculated for skin toxicities, stratified considering different oncological treatments.
Evaluation of the type of skin toxicities related to oncological treatment5 yearsData will be described using absolute and (percentage) relative frequencies calculated for specific types of skin toxicities collected by the participating centers. Specific types of skin toxicities will be defined during dermatologists involved in the study, based on subjects enrolled at each site.
Evaluation of the severity of skin toxicities related to oncological treatment5 yearsGrade of severity of skin toxicities will be collected: absolute and (percentage) relative frequencies will be calculated for different grades of severity.

Secondary

MeasureTime frameDescription
Evaluation of the association between skin toxicities and overall survival5 yearsStatistical modelling of the association between skin toxicities and overall survival (OS) as drug effectiveness parameter. To evaluate overall survival, difference between date of start therapy and date of or death will be calculated. Time for patients without event (progression of disease or death) will be considered from date of start therapy and date of last contact.
Evaluation of the association between skin toxicities and baseline clinical parameters5 yearsA statistical model will be carried out, namely a mathematical relationship between presence of skin toxicities and baseline clinical parameter. Mathematical model will be a logistic regression, in which, independent variable is the presence of skin toxicities while dependent variables are parameters measured at baseline. These parameters could be continuous (for example: age of patients) or categorical (for example: gender or site of disease).
Evaluation of the optimal management of skin toxicities related to cancer treatment5 yearsData related to management of skin toxicities will be described using absolute and (percentage) relative frequencies calculated for specific types of skin toxicities collected by the participating centers.
Evaluation of the association between skin toxicities and objective response rate5 yearsStatistical modelling of the association between skin toxicities and objective response rate (ORR) as drug effectiveness parameter. To analyze objective response rate (ORR), proportion of patients with complete and partial response will be calculated, globally for all patients and considering different subgroup of treatment type.
Evaluation of the association between skin toxicities and progression-free survival5 yearsStatistical modelling of the association between skin toxicities and progression-free survival (PFS) as drug effectiveness parameter. To evaluate progression-free survival, difference between date of start therapy and date of disease progression (or death) will be calculated.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026